Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 9Thyroid Neoplasms 4Thyroid Cancer, Papillary 4Neoplasms 3Multiple Myeloma 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma, Follicular 2Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Ovarian Neoplasms 1Nonseminomatous germ cell tumor 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1Melanoma 1Lymphoproliferative Disorders 1Leukemia, Hairy Cell 1Laryngeal Neoplasms 1Histiocytosis, Langerhans-Cell 1Hematologic Neoplasms 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Erdheim-Chester Disease 1Differentiated Thyroid Cancer (DTC) 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1Adenoma, Oxyphilic 1

Interventions

trametinib 1spartalizumab 1pembrolizumab 1motesanib diphosphate 1lenvatinib 1gallium Ga 68 dotatate 1dabrafenib 1cediranib 1Sorafenib 1Sodium Iodide 1Lenalidomide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid cancer, Hurthle cell × dabrafenib × Endocrine × Clear all
NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
19 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡